FDA Inspection 1316162 — Dr. Li Zhang
The FDA completed an inspection of Dr. Li Zhang on Apr 24, 2026 in Guangzhou. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Apr 24, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Guangzhou (China)
Additional Details
Clinical Investigator (CI)